Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Metabotropic Glutamate Receptor 3 Antibodies:
anti-Mouse (Murine) Metabotropic Glutamate Receptor 3 Antibodies:
anti-Rat (Rattus) Metabotropic Glutamate Receptor 3 Antibodies:
Go to our pre-filtered search.
Our findings support the GWAS-implicated link between GRM3 genetic variation and schizophrenia risk as well as the notion that alleles conferring this risk may be population specific.
Studies support a role for NHERF-1 (show SLC9A3R1 Antibodies) and NHERF-2 (show SLC9A3R2 Antibodies) (Na+/H+ exchanger regulatory factors 1 and 2) in regulating the distribution of Group II metabotropic glutamate (show GRIN1 Antibodies) receptor (mGluRs) in the murine brain, while conversely the effects of the mGluR2 (show GRM2 Antibodies)/3 PDZ (show INADL Antibodies)-binding motifs on receptor signaling are likely mediated by interactions with other PDZ (show INADL Antibodies) scaffold proteins beyond the NHERF (show SLC9A3R1 Antibodies) proteins.
Results demonstrate that GRM3 expression is significantly upregulated in human colonic adenocarcinomas and colon cancer cell lines. This upregulation is mediated at the post-transcriptional level where miR (show MLXIP Antibodies)-487b directly targets GRM3 to suppress its translation. Also, the fact that TGFbeta (show TGFB1 Antibodies) increases GRM3 protein stability provide novel mechanisms of post-transcriptional regulation of GRM3 in colon cancer.
Low GRM3 expression is associated with multiple myeloma and B-cell leukemia.
Significant association was found between rs12704290 in GRM3 gene and schizophrenia(SCZ). A three-SNP LD spanning GRM3Delta4 splice site was significantly associated with SCZ. Interaction between the LD block and cognitive function was found in SCZ patients.
Results show that GRM3 rs274622 C carriers with schizophrenia were associated with significantly smaller prefrontal activation than patients with TT genotype
Grm3 expression was decreased in B cells from patients with autoimmune diseases such as activated systemic lupus erythematosus and multiple sclerosis.
Pharmacogenetic relationships were identified in patients with schizophrenia between GRM3 variants and symptom response to antipsychotics.
PI4KA (show PI4KA Antibodies) and GRM3 polymorphisms have potential to jointly modulate antipsychotic response
Findings suggest that mGluR2 (show GRM2 Antibodies)/3 and mGluR5s are unaltered in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia
the activation of mGluR3 up-regulates the membrane expression of TWIK-1 (show KCNK1 Antibodies) that in turn enhances NH4(+) uptake in astrocytes.
These studies provide a foundation for future research seeking to parse out the roles of mGlu2 (show GRM2 Antibodies) from mGlu3, paving the way for better understanding of how these receptors regulate activity in the brain.
provided evidence that JARID1B (show KDM5B Antibodies) via modulation of stemness-related signaling is a putative novel therapeutic target for treating malignant NB
Activation of GABA(B) or mGlu2 (show GRM2 Antibodies)/3 receptors inhibited both evoked presynaptic Ca(2 (show CA2 Antibodies)+) transients and striatal field potentials.
Activation of Grm3 ameliorates lupus-like disease in mice by reducing B cell numbers. Grm3 expression on B-cells is decreased in lupus-prone mice.
The number of mGluR3-immunoractive cells was significantly reduced in the dorsal and intermediate but not ventral parts of the lateral septum in postpartum versus virgin females.
GRM3-knockout mice exhibit a biphasic effect in spatial working memory, initially impaired but performing better after training.
The results of these studies implicate mGlu3 as a major regulator of PFC (show CFP Antibodies) function and cognition.
This study demonistrated that mGluR3 knockout mice show a working memory defect.
report we describe a novel neuroprotective function of mGlu3 receptors related to their ability to promote the non-amyloidogenic pathway of APP (show APP Antibodies) cleavage in astrocytes, thus enhancing sAPPalpha production
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities.
metabotropic glutamate receptor 3
, glutamate metabotropic receptor 3
, G protein-coupled receptor, family C, group 1, member C